4/16/2023 0 Comments Lyx double space![]() ![]() But this is also just the start and all of us at Amylyx remain steadfast and committed to the work ahead in our commercial launches and as we work to transform what it means to be diagnosed with ALS. We are very proud of our team for the way they have partnered with the ALS community and for the great progress they've made toward our goal of delivering RELYVRIO to every eligible person in the U.S. Since the approval, we have seen strong interest in RELYVRIO, and we are encouraged by the early success of our commercial launch. We believe our therapy represents a meaningful advancement in treatment options for people living with ALS. following its approval with conditions at ALBRIOZA in Canada, ALS is a relentlessly progressive and universally fatal disease and RELYVRIO is the first approved treatment for ALS to demonstrate both a statistically significant benefit in function in the clinical trial as well as an observed benefit on survival in a longer-term post-hoc analysis. And as we look back, we are very proud of the progress we've made toward our mission over those 10 years.Ģ022 was, in many ways, the most important year for us with the FDA approval of RELYVRIO for the treatment of adults with ALS in the U.S. We just celebrated Amylyx' 10th birthday. Our mission is to one day end the suffering caused by ALS and other neurodegenerative diseases. Thank you, Lindsey, and good afternoon, everyone. You are cautioned not to place any undue reliance on these forward-looking statements, and Amylyx disclaims any obligation to update such statements unless required by law. These statements include, but are not limited to, our expectations with respect to RELYVRIO and ALBRIOZA, statements regarding regulatory developments and the expected timing thereof our business strategy and outlook and our expected financial performance and cash runway.Īctual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. With me on the call are Josh Cohen and Justin Klee, our Co-CEOs and Margaret Olinger, our Chief Commercial Officer and Jim Frates, our Chief Financial Officer.īefore we begin, I would like to remind everyone that any statement we make or information presented on this call that are not historical facts are forward-looking statements that are based on our current beliefs, plans and expectations and are made pertinent to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Good afternoon, and thank you for joining us today to discuss our fourth quarter and full year 2022 earnings. I would now like to turn the call over to Lindsey Allen, Head, Investor Relations and Communications. (Operator Instructions) Please be advised that this call is being recorded at the company's request. At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings Conference Call. My name is Gary, and I will be your conference operator today. Umer Raffat Senior MD
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |